Clinical trial
Randomized Clinical Comparison of the Combined Sirolimus Eluting and Endothelial Progenitor Cell Combo™ Stent and the Biolimus Eluting Absorbable Polymer Coated BioMatrix Alpha™ Stent in Patients Treated With Percutaneous Coronary Intervention.
NCT03952273 is registered in ClinicalTrials.gov with Phillip Freeman as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Clinical Comparison of the Combined Sirolimus Eluting and Endothelial Progenitor Cell Combo™ Stent and the Biolimus Eluting Absorbable Polymer Coated BioMatrix Alpha™ Stent in Patients Treated With Percutaneous Coronary Intervention.
- Lead sponsor
- Phillip Freeman
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- August 14, 2019
- Completion date
- November 30, 2030
- Enrollment
- 3,141 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.